Jiehua Zhou

Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.

Targeting gastrin-releasing peptide receptors for cancer treatment.

Polycationic dendrimers interact with RNA molecules: polyamine dendrimers inhibit the catalytic activity of Candida ribozymes.

Cooperative binding and self-assembling behavior of cationic low molecular-weight dendrons with RNA molecules.

Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.

树形高分子高效 siRNA 交付和烈性基因沉默。

Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA/dendrimer complexes.

Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Bivalent aptamers deliver the punch.

Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.

The therapeutic potential of cell-internalizing aptamers.

Aptamer-targeted cell-specific RNA interference.

CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.

Cell-specific aptamer-mediated targeted drug delivery.

An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice.

Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.

Progress in RNAi-based antiviral therapeutics.

Aptamer-targeted RNAi for HIV-1 therapy.

Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.

Structurally flexible triethanolamine core PAMAM dendrimers are effective nanovectors for DNA transfection in vitro and in vivo to the mouse thymus.

Current Advances in Aptamers for Cancer Diagnosis and Therapy.

HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.